ALKT vs REGN · rev $333.8M vs P/E 14, rev $14.34B
Alkami Technology Inc (ALKT) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Alkami Technology Inc (ALKT) is a software - application company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported ALKT revenue for 2024-12-31 was $333.8M. Net income was -$40.8M. Revenue was up 26.1% from 2023-12-31 to 2024-12-31. ALKT currently screens at market cap $1.82B.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
ALKT currently screens at market cap $1.82B. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the ALKT and REGN stock pages for the full models.
Not investment advice.